A Prospective Study on Level of Concordance Between Core Needle Biopsy and Surgical Specimen for Assessing Oestrogen Receptor, Progesterone Receptor, and Her2/Neu Receptor Status in Carcinoma Breast and Its Implications on Treatment Decisions

Damodaran, Dileep; Naidu, Bhupathi K; Varghese, Jenimol Chacko; Rajan, Prabha; Kuruvilla, Rojan; Kuruvilla, Shalini

doi:10.1007/s13193-020-01146-y

Cited by 3 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bu reseptörlerin sonuçları, doku işleme, soğuk iskemi süresi, fiksasyonun yeterliliği ve İHK test tekniği gibi çeşitli faktörlerden etkilenir. TİB'lerde soğuk iskemi süresinin nerdeyse sıfır olduğu ve boyutu küçük olduğu için daha iyi fikse olduğu düşünülür [25]. Genel olarak, literatürde TİB ve rezeksiyon materyali arasındaki uyum oranının ER için PgR'den daha yüksek olduğunu öne sürülmektedir.…”

Section: Discussionunclassified

“…Cerrahi rezeksiyon örneklerine ve daha büyük numunelere özgü fiksasyon hataları nedeniyle TİB'de, ER, PgR ve HER2 reseptör durumu daha iyi tahmin edilmektedir [25]. Ancak meme kanseri tümörlerinde immünohistokimya biyobelirteçlerinin heterojen ekspresyonu, TİB'nin tüm hastalarda gerçek biyolojik profili yeterince temsil etmeyebileceği endişesini ortaya çıkarmaktadır.…”

Section: Discussionunclassified

See 1 more Smart Citation

Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?

Karakaya¹,

Yılmaz²,

Karabaş³

2021

Pamukkale Medical Journal

View full text Add to dashboard Cite

Makale bilim dalı: Patoloji Başlık: Meme kanseri trucut iğne biyopsi ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı? Kısa başlık: Meme tümörü trucut ve rezeksiyon materyalleri arasında histopatolojik uyum. Özet Amaç: Meme kanseri tanısı almış olgularda, trucut iğne biyopsi (TİB) ve rezeksiyon materyalleri arasında, tanısal uyum, histolojik derece, moleküler alt tipleri, östrojen reseptörü (ER), progesteron reseptörü (PgR) ve insan epidermal büyüme faktörü reseptörü 2 (HER2) düzeylerinin karşılaştırılarak sonuçların literatür eşliğinde değerlendirilmesi amaçlanmıştır. Gereç ve yöntem: 2018 Mayıs-2020 Kasım tarihleri arasında, Pamukkale Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı'nda tanı almış 64 olguya ait TİB ve aynı hastaların rezeksiyon materyalleri çalışmaya alınmıştır. TİB ve rezeksiyon materyallerinde tümör tipi, derecesi, moleküler alt tipleri ve immunohistokimyasal olarak ER, PgR, HER2, Ki-67 ve moleküler FISH yöntemi ile HER2 durumuna ait patolojik bilgiler retrospektif olarak incelenmiştir. Bulgular: TİB tanı verilebilen lezyonlar ile rezeksiyon materyallerinin histolojik tipi arasındaki uyum oranı %93,75'tir. ER, PgR, HER2 uyum oranları sırasıyla, %89 (kappa, 0,685, p<0,001), %81,8 (kappa, 0,645, p<0,001), %95 (kappa=8,68, p<0,001)'tir. HER2 uyum oranı, ER ve PgR reseptör uyum oranına göre daha iyidir. Ki-67'ye baktığımızda %79 oranında, orta düzeyde uyum (kappa, 0,447, p<0,001) görülmüştür. Derece karşılaştırmasında %79 uyum oranı ile iyi uyum (kappa, 0,637, p<0,001) bulunmuştur. Moleküler sınıflama arasında uyum oranı %93 olup, çok iyi uyum (kappa, 0,882, p<0,001) bulunmuştur. Lüminal A en fazla görülen tip olup, uyum oranı %97'tür. Sonuç: Tanısal biyopsi ve rezeksiyon materyalleri arasında yüksek oranda uyum görülmüştür. TİB'lerin tümörün histopatolojik özelliklerinin belirlenmesi, tanı, tedavi ve prognozda önemi olan ER, PgR, HER2, Ki-67 immünhistokimyasal boyamalarının çalışılması için güvenilir materyaller olduğu sonucuna varılmıştır. Ayrıca Ki-67, HER2 negatif tümörlerin moleküler subtiplemesinde önemli olduğu görülmüştür.

show abstract

Section: Discussionunclassified

Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?

Karakaya¹,

Yılmaz²,

Karabaş³

2021

Pamukkale Medical Journal

View full text Add to dashboard Cite

show abstract

“…Overall, these percentage figures show variable concordance between CNB and SE specimens rather than ER, PR and HER2. Damodaran et al 16 showed that concordance between CNB and SE in 90 patient samples for ER, PR and HER2 were 92, 88 and 78%, respectively. Ensani et al 63 replicated these results in 100 samples, with concordance rates of 90, 81 and 97.3% for ER, PR and HER2.…”

Section: R E S U L T S O F T H E S T U D I E Smentioning

confidence: 99%

“…A further issue is that few studies have compared the concordance rates for Ki-67 measured in CNB and SE specimens, unlike for ER, PR and HER2, for which there is a plethora of data [16][17][18][19][20][21] confirming concordance between SE and CNB measurements. By primarily measuring Ki-67 in SE specimens, the lack of data for its concordance rates could exclude a large group of women who do not undergo primary surgical treatment (mainly older women) and patients having NACT in both clinical and reseach settings.…”

Section: Introductionmentioning

confidence: 99%

Concordance between core needle biopsy and surgical excision specimens for Ki‐67 in breast cancer – a systematic review of the literature

et al. 2021

View full text Add to dashboard Cite

Concordance between core needle biopsy and surgical excision specimens for Ki-67 in breast cancera systematic review of the literature Aims: The biomarkers oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are routinely measured in patients with breast cancer with international consensus on how they should be interpreted. There is evidence to support use of other biomarkers to give more detailed predictive and prognostic information. Ki-67 is one example, and measures the proliferative activity of cancer cells. It is important that this can be performed at diagnosis of breast cancer for patients who do not have initial surgical treatment (mainly older women) and those receiving neoadjuvant therapies. Methods and results: A systematic review was performed to assess concordance of measurement of Ki-67 between core needle biopsy (CNB) samples and surgical excision (SE) samples in patients with invasive breast cancer. MEDLINE and Embase databases were searched. Studies were eligible if performed within the last 10 years; included quantitative measurement of Ki-67 in both CNB and SE samples with no prior breast cancer treatment; measured concordance between two samples; and had full text available. A total of 22 studies, including 5982 paired CNB and SE samples on which Ki-67 was measured, were appraised. Overall, there appeared to be concordance; however, reliability was unclear. Where given, the Cohen's kappa coefficient (j) of correlation between samples ranged from 0.261 to 0.712. The concordance rate between CNB and SE where measured as a percentage had a range from 70.3 to 92.7% Conclusions: Assessment of level of concordance of Ki-67 between CNB and SE samples is hampered by different methodologies. International consensus on Ki-67 measurement is urgently needed.

show abstract

“…Breast cancer is one of the most common types of cancer worldwide and its prevalence continues to rise. Part of a good initial evaluation includes immunohistochemistry (IHC) determination of biomarker status, to decide the treatment strategy, particularly in the neoadjuvant setting [1][2][3][4][5][6][7]. Core needle biopsy (CNB) is always the choice for histologic diagnosis and the sample where biomarker evaluation is conducted [1,2,[4][5][6]8,9].…”

Section: Introductionmentioning

confidence: 99%

Her2 Status Discrepancy Between Core Needle Biopsy and Surgically Resected Mastectomy Specimen: A Clinical Case

Vasques¹,

Baleiras²,

Pinto³

et al. 2023

Cureus

View full text Add to dashboard Cite

The biomarker concordance between core needle biopsy (CNB) and surgical specimen (SS), in breast cancer, has long been a matter of discussion because of its influence on oncologic treatment choice. Particularly, human epidermal growth factor receptor 2 (Her2) status is quite important, because of the impact on breast cancer classification and target therapy. Many factors could influence the difference in biomarker status between samples, such as the technic itself, sample procedures and intratumoral heterogeneity. Neoadjuvant chemotherapy (NAC) can also contribute to this variation and should be taken into consideration. We report a clinical case of a 33-year-old man who was diagnosed with right breast cancer, initially Her2 negative in the CNB. Therefore, the NAC was completed without anti-Her2 treatment. Later, after the mastectomy, revision of the SS was found to be positive for Her2, after the silver in situ hybridization (SISH) technique. Consequently, the patient lost the chance of doing anti-Her2 therapy in the neoadjuvant setting, reducing his possibility to achieve a complete pathologic response and later jeopardizing his clinical outcome.

show abstract

A Prospective Study on Level of Concordance Between Core Needle Biopsy and Surgical Specimen for Assessing Oestrogen Receptor, Progesterone Receptor, and Her2/Neu Receptor Status in Carcinoma Breast and Its Implications on Treatment Decisions

Cited by 3 publications

References 17 publications

Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?

Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?

Concordance between core needle biopsy and surgical excision specimens for Ki‐67 in breast cancer – a systematic review of the literature

Her2 Status Discrepancy Between Core Needle Biopsy and Surgically Resected Mastectomy Specimen: A Clinical Case

Contact Info

Product

Resources

About